Deep brain stimulation (DBS) of the subcallosal cingulate white matter (SCCWM) is an experimental therapy for major depressive disorder (MDD). The specific axonal pathways that mediate the anti-depressant effects of DBS remain unknown. Patient-specific tractographyactivation models (TAMs) are a new tool to help identify pathways modulated by DBS. TAMs consist of four basic components: 1) anatomical and diffusion-weighted imaging data acquired on the patient; 2) probabilistic tractography from the brain region surrounding the implanted DBS electrode; 3) finite element models of the electric field generated by the patient-specific DBS parameter settings; 4) application of the DBS electric field to multi-compartment cable models of axons, with trajectories defined by the tractography, to predict action potential generation in specific pathways. This study presents TAM predictions from DBS of the SCCWM in one MDD patient. Our findings suggest that small differences in electrode location can generate substantial differences in the directly activated pathways.
Introduction
Deep brain stimulation (DBS) represents a promising experimental therapy for patients with depression [1, 2] . However, the target axonal pathways and most appropriate stimulation parameter settings responsible for the purported therapeutic response to DBS are not completely understood. Clinical DBS electrodes are implanted in white matter regions that connect multiple gray matter structures implicated in the origin of neuropsychiatric disorders. Diffusion-weighted imaging (DWI) in humans [3, 4] and anatomical tracing in non-human primates [5] have documented a wide range of different pathways that may be stimulated by DBS for the treatment of depression. However, we propose that the next generation analyses should include both anatomical tractography and electrical activation representations of the therapy [6] . Therefore, we created a patient-specific tractographyactivation model (TAM) to investigate DBS of the subcallosal cingulate white matter (SCCWM) in a patient with major depressive disorder (MDD).
Methods
Ethical approval from the Emory University institutional review board and informed written consent from the patient were obtained prior to enrollment in a clinical trial evaluating SCCWM DBS [2] . The patient was implanted with quadripolar DBS electrodes which were 1.4 mm in diameter and consisted of one 3 mm long contact tip followed by three 1.5 mm long contacts, separated by 1.5 mm non-conductive spacing (St. Jude Medical, St. Paul, MN) (Fig. 1A) . The results of this study compare stimulation through either contact #1 or contact #3. These contacts were independently evaluated with intra-operative testing while the patient was blind to the active contact. In prior reports [1, 2] , approximately two-thirds of patients experience positive effects from acute SCCWM DBS, including a sense of increased alertness, less psychic pain, decreased heaviness, and increased interest/ motivation. It is unclear if these effects can explicitly predict long-term antidepressant response to SCCWM DBS. The choice of contact used for long-term stimulation was primarily based on anatomical location within the SCCWM, as previously described [2] . Long-term therapeutic benefit in this patient was achieved via bilateral monopolar stimulation through contact #3 with 8 mA, 90 s pulses delivered at 130 Hz on both sides of the brain. Prior to surgery the patient had a score of 23 on the Hamilton Depression Rating Scale (HDRS17), which reduced to 5 after 1 year of stimulation through contact #3. This classified the patient as in remission, which has been sustained.
Imaging Data
A T1-weighted MRI at 3T was acquired pre-operatively (voxel size of 1 × 1 × 1 mm), along with diffusion weighted images (DWI) (b = 1000 sec/mm 2 ) acquired along 64 gradients (voxel sixe 2 × 1.94 × 1.94 mm). DWI data were pre-processed with FSL to correct for motion artifacts and Eddy currents in the gradient coils [7] . A post-operative CT image was also acquired (voxel sixe 0.48 × 0.48 × 0.62 mm) for DBS electrode localization. All imaging data was co-registered to an image with no diffusion weighting (b = 0 sec/mm 2 ) to determine the affine transformations across the different image data sets.
Tractography-Activation Models
We used TAMs to compare the stimulation effects at the most therapeutic contact (#3) versus a non-therapeutic contact (#1). TAMs combine tractography models with electric field models to predict direct axonal activation in response to specific DBS parameter settings in the patient [6, 8] . A seed volume (18 × 24 × 28 mm) encompassing the SCC region and DBS electrode was defined in the patient's structural MRI. Probabilistic tractography was performed from the seed volume with a uniform distribution of 100 streamlines from each DWI voxel using FSL [7] . These trajectories were used to define the geometry of 110,000 multi-compartment cable models of myelinated axons [9] (Fig. 1C) . Each axon model was defined using a fiber diameter of 5.7 m and thereby provided a "worst case" estimate of the spread of axonal activation during SCCWM DBS.
A finite element model (FEM) of the DBS electrode and surrounding brain tissue was created to simulate the voltage distribution generated in the brain by stimulation through each individual electrode contact [10] . The diffusion tensors, calculated at each voxel in the DWI, were transformed into conductivity tensors and integrated into the FEM to account for the anisotropy and inhomogeneity of the patient brain [11] . The extracellular voltage distribution interpolated along each axon model trajectory was used to simulate the change in transmembrane potential induced by each DBS pulse (Fig. 1D) [12] . Axons which received sufficient polarization from DBS responded with action potential generation and were deemed to be directly activated by the given stimulation parameter settings (Fig.  1E,F,G,H) .
Results
SCCWM DBS TAMs predicted robust activation of numerous pathways. For simplicity, Figure 1 shows unilateral TAM results for left side stimulation, as similar activation patterns were seen with right side simulation. DBS through the most therapeutic electrode contact (contact #3) (8 mA) resulted in direct activation of 4,131 axon models that primarily projected to/from brain regions associated with the ventromedial pre-frontal cortex (vmPFC) (i.e. BA10), nucleus accumbens, and cingulum bundle (Fig. 1E,G) . Sub-therapeutic stimulation through contact #3 (4 mA) activated the same general pathways, but only 2,465 axon models. Non-therapeutic stimulation through contact #1 (8 mA) activated 2,196 axon models which were associated with the more posterior/caudal aspects of the vmPFC (i.e. BA32) and accumbens. However, contact #1 stimulation did not activate the cingulum bundle or the rostral vmPFC (Fig. 1F,H) .
Discussion
We present a patient-specific DBS TAM where both the DWI-based tractography and electric field models were derived from imaging data acquired directly from the patient. Previous neuropsychiatric DBS tractography studies relied on DWI atlas brains that may not account for the nuances of the patient's specific neuroanatomy [3, 4, 6] . In addition, probabilistic tractography allowed us for the first time to couple our DBS axonal activation predictions with inferences of cortical and sub-cortical connectivity.
The SCCWM DBS target carries multiple fibers connecting the frontal cortex, cingulate, accumbens, thalamus, amygdala, hippocampus, and brainstem [5] . Functional imaging results confirm widespread network changes associated with DBS induced antidepressant effects [1] . Therefore, it is unlikely that a single axonal pathway fully accounts for the therapeutic effects of SCCWM DBS. Our case report suggests that activation of a critical mass of a unique combination of cortical, sub-cortical, and cingulate pathways may be necessary for therapeutic benefit.
We propose that patient-specific DBS TAMs represent a useful technique to compare pathway activation in response to DBS at different parameter settings. In addition, DBS TAMs created for populations of patients will enable comparison of pathway activation in responders vs. non-responders. Such efforts could assist in the definition of target pathways for therapeutic benefit in the range of DBS clinical applications. However, validation of TAM predictions will require integration of multiple experimental modalities such as functional imaging, electrophysiology, and anatomical tract tracing. 
